ODN 1018 sodium
Based on 2 publication(s) in Google Scholar
ODN 1018 (1018 ISS) sodium is a TLR9 agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.49%
- 分子量:7150 (free acid)
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 ODN 1018 sodium
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
生物活性
|
TLR9 |
ODN1018 (0.7 μM) sodium stimulates proliferation and IL-6 production in purified human B cells, and this stimulation is inhibited by IRS at 0.35-0.7 μM[3].
ODN1018 (0.7 μM; 48 h) sodium activates mouse splenocytes to produce IL-6 via TLR9, and this activation is dose-dependently inhibited by IRS 869 at 0.0875-0.7 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ODN 1018 (20 μg; intranasally; weekly; 1-17 weeks) sodium induces sustained suppression of allergic airway inflammation in ragweed-sensitized mice, with 5 weekly doses sufficient for durable effects associated with TReg induction[2].
ODN 1018 (50 μg; s.c.) sodium induces a lethal TLR9-mediated inflammatory response in D-galactosamine-pretreated BALB/c mice[3].
ODN 1018 (25 μg; s.c.) sodium stimulates TLR9-mediated cytokine (IL-6, IL-12) production in BALB/c mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (6-8 week old female, ragweed-sensitized allergic asthma model)[2]
-
Dosage:20 μg
-
Administration:intranasally; weekly; 1, 3, 5, 8, 12, 13, 16, or 17 weeks
-
Result:Suppressed bronchoalveolar lavage (BAL) eosinophilia, BAL IL-4, IL-5, IL-13 levels, and lung Th2-associated genes (Il13, Ccl11, Gob5, Fizz1) through 13 subsequent weekly ragweed exposures (12 weekly treatments).
Induced significant, lasting reduction of Th2-mediated responses (5 weekly treatments); Upregulated lung regulatory T cell (TReg)-associated genes (Foxp3, Il10, Tgfb1, Lag3, Tnfrsf4, Il2ra) and increased TReg activity (CD4+CD25+ T cells from treated mice suppressed CD4+CD25- T cell proliferation more effectively than those from ragweed-only mice) (16 weekly treatments).
Induced a moderate Th1 shift (progressive increase in lung Ifng, Cxcl9, Cxcl10 expression) but Th2 suppression did not require IFN-γ; Prevented ragweed-pulsed bone marrow dendritic cells from restoring Th2 responses.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
性状 Solid
-
分子量 7150 (free acid)
-
Color Off-white to light yellow
-
SMILES
[ODN 1018 (sodium)]
-
別名
1018 ISS sodium
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 May;641(8061):202-210. PMID: 40140567
ODN 1018 sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 May;641(8061):202-210. [Abstract]
Mice were immunized with ABM5-OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0 and 14.
ODN 1018 sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 May;641(8061):202-210. [Abstract]
Mice were immunized with ABM5-OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0 and 28.
-
J Ethnopharmacol
Elucidating the anti-HSV-2 mechanism of Longdan Xiegan Decoction via the TLR9 signaling pathway: A multi-omics perspective. [Abstract]2026 Jun 12:364:121470. PMID: 41791624
純度とドキュメンテーション
-
データシート (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2242 KB)
参考文献
[1]. Friedberg JW, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug;146(3):282-91. [Content Brief]
[2]. Eng NF, et al. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother. 2013 Aug;9(8):1661-72. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz